Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

被引:58
作者
Andersson, Emelie [1 ]
Persson, Sofie [1 ,2 ]
Hallen, Nino [3 ]
Ericsson, Asa [4 ]
Thielke, Desiree [3 ]
Lindgren, Peter [1 ,5 ]
Steen Carlsson, Katarina [1 ,2 ]
Jendle, Johan [6 ]
机构
[1] Swedish Inst Hlth Econ, Lund, Sweden
[2] Lund Univ, Dept Clin Sci, Hlth Econ Unit, Lund, Sweden
[3] Novo Nordisk AS, Copenhagen, Denmark
[4] Novo Nordisk Scandinavia, Malmo, Sweden
[5] Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden
[6] Orebro Univ, Inst Med Sci, Diabet Endocrinol & Metab Res Ctr, Orebro, Sweden
关键词
Costs and cost analysis; Diabetes complications; Diabetes mellitus; type; 2; Hospital costs; Insurance; disability; Sick leave; POPULATION; PREVALENCE; MELLITUS; EVENTS;
D O I
10.1007/s00125-020-05277-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis The risk of complications and medical consequences of type 2 diabetes are well known. Hospital costs have been identified as a key driver of total costs in studies of the economic burden of type 2 diabetes. Less evidence has been generated on the impact of individual diabetic complications on the overall societal burden. The objective of this study was to analyse costs of hospital-based healthcare (inpatient and outpatient care) and work absence related to individual macrovascular and microvascular complications of type 2 diabetes in Sweden in 2016. Methods Data for 2016 were retrieved from a Swedish national retrospective observational database cross-linking individual-level data for 1997-2016. The database contained information from population-based health, social insurance and socioeconomic registers for 392,200 people with type 2 diabetes and matched control participants (5:1). Presence of type 2 diabetes and of diabetes complications were derived using all years, 1997-2016. Costs of hospital-based care and of absence from work due to diabetes complications were estimated for the year 2016. Regression analysis was used for comparison with control participants to attribute absence from work to individual complications, and to account for joint presence of complications. Results Use of hospital care for complications was higher in type 2 diabetes compared with control participants in 2016: 26% vs 12% had >= 1 hospital contact; there were 86,104 vs 24,608 outpatient visits per 100,000 people; and there were 9894 vs 2546 inpatient admissions per 100,000 people (allp < 0.001). The corresponding total costs of hospital-based care for complications were euro919 vs euro232 per person (p < 0.001), and 74.7% of costs were then directly attributed to diabetes (euro687 per person). Regression analyses distributed the costs of days absent from work across diabetes complications per se, basic type 2 diabetes effect and unattributed causes. Diabetes complications amounted to euro1317 per person in 2016, accounting for possible complex interactions (25% of total costs of days absent). Key drivers of costs were the macrovascular complications angina pectoris, heart failure and stroke; and the microvascular complications eye diseases, including retinopathy, kidney disease and neuropathy. Early mortality in working ages cost an additional euro579 per person and medications used in risk-factor treatment amounted to euro418 per person. Conclusions/interpretation The economic burden of complications in type 2 diabetes is substantial. Costs of absence from work in this study were found to be greater than of hospital-based care, highlighting the need for considering treatment consequences in a societal perspective in research and policy. Graphical abstract
引用
收藏
页码:2582 / 2594
页数:13
相关论文
共 35 条
  • [1] Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up
    Adamsson Eryd, S.
    Svensson, A. -M.
    Franzen, S.
    Eliasson, B.
    Nilsson, P. M.
    Gudbjornsdottir, S.
    [J]. DIABETIC MEDICINE, 2017, 34 (03) : 411 - 418
  • [2] Long-term detrimental consequences of the onset of type 1 diabetes on annual earnings-evidence from annual registry data in 1990-2005
    Carlsson, K. Steen
    Landin-Olsson, M.
    Nystrom, L.
    Arnqvist, H. J.
    Bolinder, J.
    Ostman, J.
    Gudbjornsdottir, S.
    [J]. DIABETOLOGIA, 2010, 53 (06) : 1084 - 1092
  • [3] Drummond M., 2015, Methods for the Economic Evaluation of Health Care Programme, VFourth
  • [4] Forsakringskassan (the Swedish Social Insurance Agency), 2019, MICRODATA ANAL SOC I
  • [5] Forsakringskassan (the Swedish Social Insurance Agency), 2020, SICKN COMP
  • [6] Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data
    Gerdtham, Ulf-G
    Clarke, Philip
    Hayes, Alison
    Gudbjornsdottir, Soffia
    [J]. PHARMACOECONOMICS, 2009, 27 (01) : 81 - 90
  • [7] Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register
    Grip, Emilie Toresson
    Svensson, Ann-Marie
    Miftaraj, Mervete
    Eliasson, Bjorn
    Franzen, Stefan
    Gudbjornsdottir, Soffia
    Carlsson, Katarina Steen
    [J]. DIABETES CARE, 2019, 42 (04) : 545 - 552
  • [8] Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
    Hex, N.
    Bartlett, C.
    Wright, D.
    Taylor, M.
    Varley, D.
    [J]. DIABETIC MEDICINE, 2012, 29 (07) : 855 - 862
  • [10] Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden
    Jansson, S. P. O.
    Fall, K.
    Brus, O.
    Magnuson, A.
    Wandell, P.
    Ostgren, C. J.
    Rolandsson, O.
    [J]. DIABETIC MEDICINE, 2015, 32 (10) : 1319 - 1328